# Japan Vasomotor Symptoms Market > Japan Vasomotor Symptoms Market Research Report: Size, Share, Trend Analysis By Therapy Type (Hormonal, Non-Hormonal) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.14% - **2024:** $ 120.6 Million - **2025:** $ 129.21 Million - **2035:** $ 257.5 Million - **Key Players:** Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH) **Report ID:** MRFR/HC/49992-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/japan-vasomotor-symptoms-market-51750 --- ## Market Summary ## **Japan Vasomotor Symptoms Market Overview** As per MRFR analysis, the Japan Vasomotor Symptoms Market Size was estimated at 141 (USD Million) in 2023. The Japan Vasomotor Symptoms Market Industry is expected to grow from 150.75(USD Million) in 2024 to 650 (USD Million) by 2035. The Japan Vasomotor Symptoms Market CAGR (growth rate) is expected to be around 14.208% during the forecast period (2025 - 2035) **Key Japan Vasomotor Symptoms Market Trends Highlighted** In Japan, the vasomotor symptoms market is increasingly shaped by a number of significant trends. The aging population is a crucial driver, as a large segment of the population experiences vasomotor symptoms during menopause. The Japan National Institute of Population and Social Security Research highlights that the number of individuals aged 65 and older is steadily rising, which amplifies the demand for effective treatments and management strategies for vasomotor symptoms.  Additionally, there is an evolving focus on personalized medicine, with healthcare providers increasingly tailoring treatments to meet the specific needs of individuals suffering from these symptoms.Opportunities in this market can be captured through advancements in technology and healthcare delivery. Japan is known for its advanced healthcare system, which supports the incorporation of innovative treatments and therapies. The use of telemedicine and digital health platforms has gained traction, particularly after the COVID-19 pandemic, fostering easier access to care for patients facing vasomotor symptoms.  Furthermore, educational initiatives aimed at raising awareness about menopause and related symptoms are also on the rise, leading to greater demand for treatments. Recent trends indicate a movement towards natural and alternative therapies.Many women in Japan are exploring non-hormonal treatment options and lifestyle modifications to alleviate their discomfort. This shift can be attributed to an increasing desire for holistic health approaches and the perception that natural alternatives may offer fewer side effects.  Overall, the Japan vasomotor symptoms market displays dynamic trends shaped by demographic changes, emerging treatment options, and evolving patient preferences, creating a unique landscape for stakeholders within the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Japan Vasomotor Symptoms Market Drivers** **Rising Awareness of Menopausal Health Issues** The health effects of menopause and the vasomotor symptoms that accompany it are becoming more well recognised in Japan. As a result of a demographic trend towards an older population, the Japanese Ministry of Health, Labour, and Welfare projects a considerable increase in the number of women aged 50 and over. Vasomotor symptoms are common in this age range, and more women are looking for treatment alternatives as knowledge of these diseases rises.  Important groups like the Japan Menopause Society, which aggressively supports education and awareness campaigns on the management of menopausal symptoms and propels the Japan Vasomotor Symptoms Market Industry, further support this trend. Market expansion is encouraged by the society's educational campaigns and outreach initiatives, which point to a possible rise in the number of patients seeking treatment. **Advancements in Treatment Options** The Japan Vasomotor Symptoms Market is witnessing growth due to advancements in treatment options available for managing these symptoms. Pharmaceutical companies in Japan are investing significantly in Research and Development (R&D) to innovate newer medications and therapies. For example, recent approvals of hormone replacement therapies and non-hormonal medications have been reported by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan. Approximately 25% of the population suffering from moderate to severe vasomotor symptoms can find substantial relief from newly developed treatments. The availability of diverse treatment options enhances patient accessibility and adherence, leading to a robust market growth trajectory. **Growing Geriatric Population** Japan has one of the highest life expectancies in the world, resulting in a growing geriatric population. The World Health Organization projects that by 2030, individuals aged 65 and older will make up about 30% of Japan's total population. As women in this age group frequently experience vasomotor symptoms, this demographic shift is expected to contribute to the growth of the Japan Vasomotor Symptoms Market.  Additionally, organizations such as the Japanese Geriatric Society are actively engaged in addressing the health needs of the elderly, providing guidelines and support that can enhance the treatment scope available for vasomotor symptoms, further underpinning market expansion. **Increased Healthcare Expenditure** Japan has one of the largest healthcare systems globally, with notable government expenditure on health services. The Japanese government allocates over 10% of its Gross Domestic Product (GDP) to healthcare, as per the Ministry of Finance. This funding enables better access to healthcare services for patients experiencing vasomotor symptoms.  Furthermore, government initiatives aimed at facilitating healthcare accessibility, such as advancements in telemedicine and subsidies for specific treatments, are expected to positively impact the Japan Vasomotor Symptoms Market.As healthcare expenditure continues to rise, the availability of treatment and patient resources will likely encourage more individuals to seek help, fostering the market's growth. **Japan Vasomotor Symptoms Market Segment Insights** **Vasomotor Symptoms Market Therapy Type Insights** The Japan Vasomotor Symptoms Market consists of diverse therapy types that address the management of vasomotor symptoms, primarily through Hormonal and Non-Hormonal approaches. Hormonal therapies, such as hormone replacement therapy (HRT), remain a prevalent choice for many individuals experiencing menopausal symptoms, as they effectively mitigate the frequency and intensity of hot flashes and night sweats, which are common presentations in this demographic.  The importance of Hormonal therapies in Japan is underscored by rising awareness regarding menopause management and the significant number of women entering menopause, highlighting a growing need for effective therapeutic solutions.On the other hand, Non-Hormonal therapies are increasingly gaining traction owing to the preference for alternatives that minimize the risk of hormone-related side effects. These Non-Hormonal options encompass a range of medications, lifestyle modifications, and natural remedies, which cater to women who prefer or require alternatives to hormonal treatment due to personal health choices or contraindications.  The diversification between these two categories reflects a comprehensive approach to managing vasomotor symptoms, catering to varying patient preferences and medical advice.As public health initiatives in Japan aim to enhance education around menopausal health and symptom management, both Hormonal and Non-Hormonal therapies are poised to play pivotal roles in addressing the growing expectations of women's health services. The Japan Vasomotor Symptoms Market operates within a framework shaped by cultural sensitivities and health policies that recognize the importance of comprehensive and individualized treatment plans. Furthermore, advancements in pharmacological research are likely to yield novel Non-Hormonal treatments, expanding available options for managing this prevalent health concern.Consequently, as the population ages and the conversation around women's health evolves, both therapy types are expected to exert a substantial influence on how vasomotor symptoms are understood and treated across Japan’s health landscape, reflecting ongoing trends and shifts in consumer preferences for menopause management. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Vasomotor Symptoms Market Distribution Channel Insights** The Distribution Channel for the Japan Vasomotor Symptoms Market plays a crucial role in ensuring the availability of treatment options to a wide demographic. Hospital pharmacies are vital as they provide immediate access to medications for patients undergoing clinical care, thus facilitating better health outcomes. Retail pharmacies cater to the general public, offering convenience and a broader range of over-the-counter options, which is essential given the aging population in Japan, where rising awareness about vasomotor symptoms is prevalent.Additionally, online stores have gained significant traction, particularly post-pandemic, allowing patients to purchase medications discreetly and conveniently from their homes.  This channel is increasingly important as digital health solutions become more integrated into the healthcare landscape, fostering accessibility and flexibility in obtaining necessary treatments. The Japan Vasomotor Symptoms Market continues to evolve with these distribution channels, reflecting changing consumer behaviors and preferences. The overall market growth is further supported by Japan's focus on enhancing healthcare infrastructure and investment in digital technologies, creating a conducive environment for these distribution channels to thrive and cater effectively to patients' needs. **Japan Vasomotor Symptoms Market Key Players and Competitive Insights** The Japan Vasomotor Symptoms Market presents a highly competitive landscape characterized by ongoing advancements in treatment solutions and persistent demand for effective management of vasomotor symptoms, particularly in the context of menopause. The increasing awareness among the population regarding menopausal health and related symptoms has propelled various pharmaceutical companies to invest in research and development, tailored therapeutics, and innovative delivery systems to meet the evolving needs of patients. Moreover, the regulatory environment in Japan influences the market dynamics, with approvals and market access strategies significantly impacting competition among key players.  The interplay of localized marketing strategies and the effectiveness of therapeutic agents plays a vital role in determining market share and growth opportunities for participants in this sector.AbbVie Inc. has established a significant presence in the Japan Vasomotor Symptoms Market through its robust portfolio focused on hormonal therapies and symptom management. Its strengths lie not only in its extensive research and development capabilities but also in its strong relationships with healthcare providers and patients, which facilitate effective outreach and education concerning vasomotor symptoms.  AbbVie has adopted a comprehensive approach to address patient needs in Japan, focusing on enhancing treatment accessibility and fostering collaboration with local health authorities. The company’s strong financial backing and commitment to innovation enable it to pursue cutting-edge therapies that effectively alleviate symptoms, maintaining a competitive edge within the market. Teva Pharmaceutical Industries Ltd holds a noteworthy position in the Japan Vasomotor Symptoms Market with a diverse and well-rounded portfolio of products aimed at managing menopausal symptoms effectively. The company's emphasis on affordability and accessibility allows it to penetrate various market segments, catering to a broad demographic of women experiencing vasomotor symptoms.  Teva benefits from its substantial experience in the pharmaceutical industry, alongside a strategic approach to mergers and acquisitions aimed at expanding its therapeutic offerings. The company frequently aligns its product development initiatives with prevalent patient needs within Japan, fostering organic growth and enhancing its competitive stature. Teva’s commitment to addressing the specific requirements of the Japanese market exemplifies its strength in navigating regulatory frameworks and fostering patient-centric solutions, further solidifying its role in the landscape of vasomotor symptom management. **Key Companies in the Japan Vasomotor Symptoms Market Include** **Japan Vasomotor Symptoms Market Industry Developments** Recent developments in the Japan Vasomotor Symptoms Market have been shaped by various strategic actions from key players. In October 2023, AbbVie Inc. announced advancements in its product portfolio aimed at treating vasomotor symptoms, with a focus on enhancing patient care in Japan. Teva Pharmaceutical Industries Ltd and Johnson and Johnson have been actively working on competitive therapies, addressing the growing demand for effective solutions in this segment. Moreover, Eli Lilly and Company has launched campaigns to raise awareness and improve patient access to treatments.  In addition to product advancements, the market witnessed some merger and acquisition activity; for instance, Merck and Co., Inc. recently expanded its footprint in Japan through a strategic partnership aimed at bolstering its position in the vasomotor symptoms sector. These activities reflect a trend of consolidation and collaboration among major players like Bayer AG and Takeda Pharmaceutical Company Limited, emphasizing the importance of innovation in addressing menopause-related symptoms. As the market valuation continues to rise, driven by an aging population and increasing awareness of hormonal health, all major companies are poised to adapt and expand their offerings to meet patient needs effectively. **Japan Vasomotor Symptoms Market Segmentation Insights** ## Market Drivers ### Integration of Telehealth Services The integration of telehealth services in Japan is emerging as a transformative factor for the vasomotor symptoms market. Telehealth platforms enable women to access healthcare professionals remotely, facilitating consultations and treatment plans without the need for in-person visits. This is particularly beneficial for those who may feel uncomfortable discussing menopausal symptoms face-to-face. The convenience and accessibility of telehealth services are likely to encourage more women to seek help for their vasomotor symptoms, potentially increasing market demand. As of 2025, it is estimated that telehealth usage in Japan has surged by over 50%, indicating a shift in how healthcare is delivered and accessed, which may further enhance the vasomotor symptoms market. ### Rising Awareness of Menopausal Health The increasing awareness surrounding menopausal health in Japan appears to be a significant driver for the vasomotor symptoms market. As more women become informed about the symptoms associated with menopause, including hot flashes and night sweats, there is a growing demand for effective treatments. Reports indicate that approximately 70% of women experience vasomotor symptoms during menopause, which underscores the necessity for targeted therapies. This heightened awareness is likely to lead to increased consultations with healthcare professionals, thereby boosting the market for vasomotor symptom management solutions. Furthermore, educational campaigns by health organizations are contributing to this trend, promoting discussions about menopause and its associated challenges, which may further stimulate market growth. ### Advancements in Pharmaceutical Research Recent advancements in pharmaceutical research are poised to impact the vasomotor symptoms market positively. Innovative drug formulations and delivery systems are being developed to enhance the efficacy and safety of treatments for vasomotor symptoms. For instance, new hormonal and non-hormonal therapies are being introduced, which may cater to the diverse needs of women experiencing these symptoms. The Japanese pharmaceutical industry has seen an increase in investment in research and development, with expenditures reaching approximately ¥1 trillion in recent years. This investment is likely to yield new treatment options that could significantly improve the quality of life for women suffering from vasomotor symptoms, thus driving market growth. ### Aging Population and Increased Incidence Japan's demographic shift towards an aging population is a crucial factor influencing the vasomotor symptoms market. With a significant portion of the population entering menopause, the incidence of vasomotor symptoms is expected to rise. Current statistics suggest that by 2030, nearly 30% of the Japanese population will be over 65 years old, leading to a higher prevalence of menopausal women. This demographic trend indicates a growing need for effective management options for vasomotor symptoms, as older women are more likely to seek treatment for these disruptive symptoms. Consequently, pharmaceutical companies and healthcare providers are likely to focus on developing innovative therapies tailored to this demographic, thereby expanding the vasomotor symptoms market. ### Cultural Shifts Towards Health and Wellness Cultural shifts in Japan towards health and wellness are influencing the vasomotor symptoms market. There is a growing trend among women to prioritize their health, leading to increased interest in holistic and integrative approaches to managing menopausal symptoms. This shift is reflected in the rising popularity of wellness programs and lifestyle modifications aimed at alleviating vasomotor symptoms. Additionally, the market for dietary supplements and alternative therapies is expanding, as women seek natural solutions to manage their symptoms. Reports indicate that the wellness industry in Japan is projected to grow by 10% annually, suggesting a favorable environment for the vasomotor symptoms market as women increasingly seek comprehensive health solutions. ## Future Outlook The [Vasomotor Symptoms Market](https://www.marketresearchfuture.com/reports/vasomotor-symptoms-market-9810) in Japan is projected to grow at a 7.14% CAGR from 2025 to 2035, driven by increasing awareness and innovative treatment options. **New opportunities:** - Development of telehealth platforms for remote patient monitoring - Investment in personalized medicine targeting specific demographics - Expansion of over-the-counter treatment options in pharmacies By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Hormonal (Largest) vs. Non-Hormonal (Fastest-Growing) In the Japan vasomotor symptoms market, the distribution of market share among the 'Type' segment values shows a significant preference for hormonal treatments, which dominate the landscape due to their effective management of symptoms. On the other hand, non-hormonal options are capturing a growing portion of the market, appealing to consumers seeking alternatives without hormonal influences. Overall, this indicates a varied consumer base with different needs and preferences, which influences purchasing behaviors. Current trends in this segment reveal a robust growth trajectory for non-hormonal products, driven by rising awareness and increasing advocacy for alternative treatments. This has led to innovations in formulation and delivery mechanisms, catering to diverse patient profiles. As healthcare professionals increasingly recommend these alternatives, the market is witnessing a shift, allowing non-hormonal treatments to emerge as a viable and sought-after choice alongside traditional hormonal therapies. Type: Hormonal (Dominant) vs. Non-Hormonal (Emerging) Hormonal treatments have established themselves as the dominant choice in the market, primarily due to their historical effectiveness in alleviating vasomotor symptoms associated with menopause. These treatments typically include estrogen therapies that have long been the mainstay for symptomatic relief. In contrast, non-hormonal options, categorized as emerging, are gaining traction rapidly, especially among those concerned about the side effects of hormonal medications. These alternatives include various herbal supplements and lifestyle interventions that appeal to health-conscious consumers. The growth of non-hormonal therapies in the Japan vasomotor symptoms market reflects a broader trend towards individualized treatment approaches, providing patients with varied options that suit their health preferences. ### By Distribution Channel: Retail Pharmacies (Largest) vs. Online Stores (Fastest-Growing) The distribution of the market share among distribution channels indicates that retail pharmacies hold a dominant position within the Japan vasomotor symptoms market, catering to a significant portion of consumers needing these treatments. Following retail pharmacies, hospital pharmacies also represent a notable share, but online stores are gaining traction as a preferred option for convenience and accessibility, showcasing the evolving preferences among consumers. Growth trends in this segment highlight an increasing shift towards online stores, fueled by the rising penetration of digital health solutions and the growing consumer preference for hassle-free shopping experiences. Retail pharmacies, while still leading, must adapt to this changing landscape by enhancing their service offerings. The combination of convenience, competitive pricing, and the accessibility of online platforms are key drivers for this shift, promising a dynamic future for the distribution landscape. Retail Pharmacies (Dominant) vs. Online Stores (Emerging) Retail pharmacies serve as the backbone of the Japan vasomotor symptoms market, characterized by their extensive reach and established customer loyalty. They provide patients with immediate access to medications, allowing for quick response times during treatment. Meanwhile, online stores are emerging as significant players, offering an innovative approach to purchasing that aligns with the growing demand for digital solutions. This segment caters to tech-savvy consumers who prioritize convenience and often provide competitive pricing due to lower operational costs. As the market evolves, both distribution channels will need to innovate and cater to consumer preferences, balancing traditional retail strengths with the growing trend of e-commerce. ## Competitive Benchmarking The vasomotor symptoms market in Japan is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Pfizer Inc (US), AbbVie Inc (US), and AstraZeneca PLC (GB) are actively engaged in enhancing their product offerings and expanding their market presence. Pfizer Inc (US) has been particularly focused on leveraging its extensive research capabilities to develop novel therapies aimed at alleviating vasomotor symptoms, which are prevalent among menopausal women. This strategic emphasis on innovation positions Pfizer as a leader in addressing unmet medical needs within this demographic.The market structure appears moderately fragmented, with several companies vying for market share through localized manufacturing and optimized supply chains. Companies are increasingly localizing their operations to better cater to the specific needs of the Japanese population, which may enhance their competitive edge. The collective influence of these key players suggests a dynamic environment where collaboration and strategic maneuvering are essential for sustained growth. In September AbbVie Inc (US) announced a partnership with a local biotechnology firm to co-develop a new treatment for vasomotor symptoms. This collaboration is expected to expedite the development process and enhance AbbVie's ability to deliver tailored solutions to the Japanese market. Such strategic alliances not only bolster AbbVie's research capabilities but also signify a commitment to addressing local healthcare challenges. In October AstraZeneca PLC (GB) launched a digital health initiative aimed at improving patient engagement and adherence to treatment regimens for vasomotor symptoms. This initiative reflects a broader trend towards digitalization in healthcare, where technology is utilized to enhance patient outcomes. By integrating digital tools into their offerings, AstraZeneca is likely to strengthen its market position and foster deeper connections with healthcare providers and patients alike.Moreover, in August 2025, Hoffmann-La Roche Ltd (CH) expanded its product portfolio by introducing a new formulation specifically designed for the Japanese market. This strategic move not only diversifies Hoffmann-La Roche's offerings but also demonstrates an understanding of local patient needs, which is crucial in a competitive landscape. Such adaptations may enhance customer loyalty and market penetration. As of November the competitive trends in the vasomotor symptoms market are increasingly defined by digital transformation, sustainability initiatives, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, allowing companies to pool resources and expertise to navigate the complexities of the market. Looking ahead, it appears that competitive differentiation will increasingly hinge on innovation and technological advancements rather than solely on price. Companies that prioritize supply chain reliability and patient-centric solutions are likely to emerge as leaders in this evolving landscape. ## Recent News & Developments Recent developments in the Japan Vasomotor Symptoms Market have been shaped by various strategic actions from key players. In October 2023, AbbVie Inc. announced advancements in its product portfolio aimed at treating vasomotor symptoms, with a focus on enhancing patient care in Japan. Teva Pharmaceutical Industries Ltd and Johnson and Johnson have been actively working on competitive therapies, addressing the growing demand for effective solutions in this segment. Moreover, Eli Lilly and Company has launched campaigns to raise awareness and improve patient access to treatments.  In addition to product advancements, the market witnessed some merger and acquisition activity; for instance, Merck and Co., Inc. recently expanded its footprint in Japan through a strategic partnership aimed at bolstering its position in the vasomotor symptoms sector. These activities reflect a trend of consolidation and collaboration among major players like Bayer AG and Takeda Pharmaceutical Company Limited, emphasizing the importance of innovation in addressing menopause-related symptoms. As the market valuation continues to rise, driven by an aging population and increasing awareness of hormonal health, all major companies are poised to adapt and expand their offerings to meet patient needs effectively. ## Report Scope | MARKET SIZE 2024 | 120.6(USD Million) | | --- | --- | | MARKET SIZE 2025 | 129.21(USD Million) | | MARKET SIZE 2035 | 257.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.14% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Pfizer Inc (US), Bristol-Myers Squibb Company (US), AbbVie Inc (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd (IL), Hoffmann-La Roche Ltd (CH), AstraZeneca PLC (GB), Novartis AG (CH) | | Segments Covered | Type, Distribution Channel | | Key Market Opportunities | Emerging therapies targeting hormonal balance present opportunities in the vasomotor symptoms market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition in the vasomotor symptoms market amid evolving regulatory frameworks. | | Countries Covered | Japan | ## Frequently Asked Questions **Q: What was the market valuation of the Japan vasomotor symptoms market in 2024?** A: The market valuation was $120.6 Million in 2024. **Q: What is the projected market valuation for the Japan vasomotor symptoms market by 2035?** A: The projected valuation for 2035 is $257.5 Million. **Q: What is the expected CAGR for the Japan vasomotor symptoms market during the forecast period 2025 - 2035?** A: The expected CAGR is 7.14% during the forecast period 2025 - 2035. **Q: Which companies are considered key players in the Japan vasomotor symptoms market?** A: Key players include Pfizer Inc, Bristol-Myers Squibb Company, AbbVie Inc, Mylan N.V., Teva Pharmaceutical Industries Ltd, Hoffmann-La Roche Ltd, AstraZeneca PLC, and Novartis AG. **Q: What are the two main types of products in the Japan vasomotor symptoms market?** A: The two main types are hormonal and non-hormonal products. **Q: What were the market values for hormonal and non-hormonal products in 2024?** A: In 2024, hormonal products were valued at $40.2 Million, while non-hormonal products were valued at $80.4 Million. **Q: How do hospital pharmacies compare to retail pharmacies in terms of market value for vasomotor symptoms?** A: In 2024, hospital pharmacies had a market value of $30.18 Million, whereas retail pharmacies had a higher value of $48.24 Million. **Q: What is the market value for online stores in the Japan vasomotor symptoms market as of 2024?** A: The market value for online stores was $42.18 Million in 2024. **Q: What is the anticipated growth trend for the Japan vasomotor symptoms market?** A: The market is anticipated to grow significantly, reaching $257.5 Million by 2035. **Q: What distribution channels are utilized in the Japan vasomotor symptoms market?** A: Distribution channels include hospital pharmacies, retail pharmacies, and online stores. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/japan-vasomotor-symptoms-market-51750*